For best experience please turn on javascript and use a modern browser!
You are using a browser that is no longer supported by Microsoft. Please upgrade your browser. The site may not present itself correctly if you continue browsing.

The incidence of melanoma is rising globally, likely caused by an increased exposure to sunlight, better detection and an increasing life expectancy. Max Madu aims to improve risk prediction in stage 3 melanoma and focuses on refining the indication of surgery and follow-up in stage 3 melanoma.

Event details of Adjuvant therapy in stage 3 melanoma
Date 13 September 2018
Time 14:00 -15:00
Location Agnietenkapel
Room Location

M.F. Madu, Who Needs Adjuvant Therapy in Stage III Melanoma?

Supervisor

Prof. E.J.T. Rutgers

Co-supervisors

Dr. A.C.J. van Akkooi
Dr M.W.J.M. Wouters

Agnietenkapel

Room Location

Oudezijds Voorburgwal 229 - 231
1012 EZ Amsterdam

Entrance

This event is open to the public.